Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22223357 | 0.78 | F2 (0.33) | KMT2APOLBPLA2G4A | |
| SCHEMBL22223433 | 0.78 | AKT1 (0.35) | KMT2APOLB | |
| SCHEMBL22223477 | 0.76 | KMT2A (0.42) | KMT2A | |
| SCHEMBL22223294 | 0.72 | DNM1 (0.38) | KMT2APOLBDNM1SLC6A5NOD1 | |
| SCHEMBL29336456 | 0.71 | SLC6A5 (0.48) | KMT2APOLBSLC6A5NOD1FOLH1 | |
| SCHEMBL22223355 | 0.71 | FFAR4 (0.45) | KMT2A | |
| SCHEMBL20450607 | 0.70 | SLC6A5 (0.47) | KMT2APOLBSLC6A5NOD1FOLH1 | |
| SCHEMBL20450528 | 0.70 | SLC6A5 (0.50) | KMT2ASLC6A5NOD1FOLH1 | |
| SCHEMBL20450608 | 0.70 | SLC6A5 (0.47) | KMT2APOLBSLC6A5NOD1FOLH1 | |
| SCHEMBL20450527 | 0.70 | SLC6A5 (0.50) | KMT2ASLC6A5NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
| WO-2020146521-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | KMT2A 616/4885POLB 2894/4885PLA2G4A 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.